How is Surgery Partners Inc.’s (NASDAQ: SGRY) stock expected to perform amid current market woes?

The price of Surgery Partners Inc. (NASDAQ: SGRY) closed at $31.06 in the last session, down -0.22% from day before closing price of $31.13. In other words, the price has decreased by -$0.07 from its previous closing price. On the day, 721583 shares were traded. SGRY stock price reached its highest trading level at $31.33 during the session, while it also had its lowest trading level at $29.93.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



We take a closer look at SGRY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.48 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 52.40. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 1.31 whereas as Long-Term Debt/Eq ratio is at 1.28.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on November 23, 2022, Reiterated its Outperform rating but revised its target price to $48 from $58 previously.

On June 15, 2022, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $55 to $36.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 15 when Evans Jason Eric sold 99 shares for $30.10 per share. The transaction valued at 2,980 led to the insider holds 414,056 shares of the business.

Baldock Jennifer sold 33 shares of SGRY for $995 on Mar 15. The Chief Admin & Dev Officer now owns 169,431 shares after completing the transaction at $30.14 per share. On Mar 15, another insider, TAPARO ANTHONY, who serves as the Chief Growth Officer of the company, sold 32 shares for $30.10 each. As a result, the insider received 963 and left with 95,784 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1.61 while its Price-to-Book (P/B) ratio in mrq is 1.59.

Stock Price History:

Over the past 52 weeks, SGRY has reached a high of $63.87, while it has fallen to a 52-week low of $20.46. The 50-Day Moving Average of the stock is 32.52, while the 200-Day Moving Average is calculated to be 30.53.

Shares Statistics:

According to the various share statistics, SGRY traded on average about 663.32K shares per day over the past 3-months and 655.9k shares per day over the past 10 days. A total of 102.00M shares are outstanding, with a floating share count of 53.58M. Insiders hold about 0.20% of the company’s shares, while institutions hold 83.00% stake in the company. Shares short for SGRY as of Jan 12, 2023 were 5.04M with a Short Ratio of 4.67M, compared to 4.3M on Dec 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.11% and a Short% of Float of 8.19%.

Earnings Estimates

The company has 9 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.18 for the current quarter, with a high estimate of $0.28 and a low estimate of $0.08, while EPS last year was $0.23. The consensus estimate for the next quarter is $0.06, with high estimates of $0.09 and low estimates of $0.01.

Analysts are recommending an EPS of between $0.18 and -$0.07 for the fiscal current year, implying an average EPS of $0.05. EPS for the following year is $0.44, with 9 analysts recommending between $0.69 and -$0.14.

Revenue Estimates

According to 8 analysts, the current quarter’s revenue is expected to be $688.7M. It ranges from a high estimate of $705.7M to a low estimate of $666.81M. As of the current estimate, Surgery Partners Inc.’s year-ago sales were $610.2M, an estimated increase of 12.90% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $666.69M, an increase of 11.80% less than the figure of $12.90% in the same quarter last year. There is a high estimate of $678.3M for the next quarter, whereas the lowest estimate is $654.49M.

A total of 10 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $2.54B, while the lowest revenue estimate was $2.5B, resulting in an average revenue estimate of $2.52B. In the same quarter a year ago, actual revenue was $2.23B, up 13.40% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $2.81B in the next fiscal year. The high estimate is $2.9B and the low estimate is $2.72B. The average revenue growth estimate for next year is up 11.50% from the average revenue estimate for this year.